Page 46 - Eceptor News Today

Critical COVID-19 illness reveals genetic associations with immunomodulatory therapies, as identified in a comprehensive analysis of 24,202 cases. This study uncovers novel genome-wide significant associations, highlighting potential druggable targets for inflammatory signaling, immunometabolism, and viral replication, offering insights into therapeutic implications.

The first investigator-initiated study of remote pulmonary artery pressure monitoring has found that it improves quality of life and reduces heart failure hospitalizations in patients with chronic heart failure.

New research presented at this year's European Congress on Obesity (ECO2023, Dublin, 17-20 May) shows that the obesity drug semaglutide is effective for weight loss in a multicentre, 1-year-long real-world study.

Research discusses the emergence of a highly diversified SARS-CoV-2 Omicron subvariant called XBB, which is spreading rapidly around the world. XBB emerged through the recombination of two cocirculating BA.2 lineages, BJ.1 and BM.1.1.1, during the summer of 2022.

Since the start of the COVID-19 pandemic, a class of corticosteroids called glucocorticoids (GCs) have become established as one of the main treatment options, especially for severe cases, thanks to their anti-inflammatory and immunosuppressant action.

A new analysis of SURMOUNT-1, the first Phase 3 study of tirzepatide in adults for chronic weight management shows that tirzepatide improves body composition across a range of adult age groups.

At Pittcon 2023 in Philadelphia, Pennsylvania, we spoke to this year's recipient of the Ralph N. Adams Award in Analytical Chemistry, Professor Joseph Wang to discuss the versatility of biosensor technologies.

Researchers generated six human monoclonal antibodies that prevented infection.

Research explores the role of ATP as a potential neurotransmitter in stimulating kisspeptin neurons to induce ovulation in rodents. The findings shed light on the neurobiological mechanisms involved in ovulation and may have implications for understanding and treating ovulation disorders.

Researchers at Children's Hospital of Philadelphia (CHOP) and the University of California, Los Angeles (UCLA) have developed a computational platform capable of discovering tumor antigens derived from alternative RNA splicing, expanding the pool of cancer immunotherapy targets.